At Imbria, our mission is to translate our understanding of cellular metabolism into medicines that improve the lives of patients with limited or inadequate treatment options.
Developing new treatments for cardiometabolic disorders
![](/media/c04nvjkx/imbria_images_pipette.jpg?center=0.61395038327193829,0.60401831129196337&mode=crop&width=960&height=1280&rnd=133028860082470000)
![](/media/1nzlpmvr/imbria_images_patient_reassurance.jpg?anchor=center&mode=crop&width=960&height=1280&rnd=133028843889400000)
Patients & Physicians
Turning our knowledge of cellular metabolism into new medicines that improve the lives of patients
Latest news
Positive Results for Patients with Non-obstructive Hypertrophic Cardiomyopathy Treated with Ninerafaxstat in the Phase 2 IMPROVE-HCM Trial Presented During a Late-Breaking Clinical Trial Session at ACC.24
Read moreApril 08, 2024
ACC.24 Late-Breaking IMPROVE-HCM Presentation
April 08, 2024